Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

Autor: van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W.M., Zweegman, S., Ossenkoppele, G. J., Schuurhuis, G. J.
Přispěvatelé: Hematology, Human genetics, Hematology laboratory
Jazyk: angličtina
Rok vydání: 2007
Předmět:
Zdroj: van Rhenen, A, Moshaver, B, Kelder, A, Feller, N, Nieuwint, A W M, Zweegman, S, Ossenkoppele, G J & Schuurhuis, G J 2007, Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission . in Leukemia . Leukemia, vol. 21, Nature Publishing Group, pp. 1700-1707 . https://doi.org/10.1038/sj.leu.2404754
Leukemia, 1700-1707
STARTPAGE=1700;ENDPAGE=1707;TITLE=Leukemia
DOI: 10.1038/sj.leu.2404754
Popis: Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38- population survives chemotherapy and is most probable the cause of minimal residual disease (MRD). The outgrowth of MRD causes relapse and MRD can therefore serve as a prognostic marker. The key role of leukemogenic CD34+CD38- cells led us to investigate whether they can be detected under MRD conditions. Various markers were identified to be aberrantly expressed on the CD34+CD38- population in AML and high-risk MDS samples at diagnosis, including C-type lectin-like molecule-1 and several lineage markers/marker-combinations. Fluorescent in situ hybridization analysis revealed that marker-positive cells were indeed of malignant origin. The markers were neither expressed on normal CD34+CD38- cells in steady-state bone marrow (BM) nor in BM after chemotherapy. We found that these markers were indeed expressed in part of the patients on malignant CD34+CD38- cells in complete remission, indicating the presence of malignant CD34+CD38- cells. Thus, by identifying residual malignant CD34+CD38- cells after chemotherapy, MRD detection at the stem cell level turned out to be possible. This might facilitate characterization of these chemotherapy-resistant leukemogenic cells, thereby being of help to identify new targets for therapy.
Databáze: OpenAIRE
Externí odkaz: